Moonshot AI, founded in March 2023, is dedicated to finding the optimal solution for converting energy into intelligence and creating versatile new productive forces. It has launched Kimi, an intelligent assistant capable of deep thinking, multimodal reasoning, and processing 200,000-word long texts.

Unitree Robotics is a pioneering company in the research, production, and sales of consumer and industrial-grade high-performance quadruped robots and dexterous six-axis robotic arms. As one of the earliest companies globally to commercialize quadruped robots, its products are widely used in agriculture, industry, security inspections, exploration, public rescue, and medical care.

RELX Technology (NYSE:RLX) is a consumer electronic cigarette company founded in China. Its main business is the development, design, and sales of RELX electronic cigarettes. With its advanced technology and product, its mission is to accelerate the transformation of the world’s one billion smokers, and bring to them healthier and happier lifestyles. RELX’s motto is, “Smoking can be delightful and carefree.”​
​RELX (NYSE:RLX) was founded in 2017, and has attracted numerous leading Venture Capital investments from Source Code Capital and IDG Capital. Currently, RELX has offices in Beijing, Shanghai, and Shenzhen, and has plans to expand internationally to better serve its global customer base. RELX’s founding team members come from renowned consumer electronics, FMCG, internet, consulting and investment companies, such as P&G, L'Oreal, Unilever, Huawei, Oppo, Mercedes-Benz, and Bain & Consulting.​

Beijing DP Technology is a pioneer in AI-driven scientific innovation, leveraging its cutting-edge "AI for Science" approach to accelerate breakthroughs across pharmaceuticals, energy, and materials science. The DP Particle Universe integrates advanced pre-trained models with specialized platforms like Hermite® for drug design and Piloteye® for battery development, bridging research with industrial applications. By combining AI-powered tools with an open scientific ecosystem, DP is redefining how industries solve complex R&D challenges and bring discoveries to market faster.

Beijing Xianglu Technology is a hard-tech company dedicated to improving food service quality through its Robot + Food strategy. Its flagship product, the Meishan Lion smart cooking robot, authentically replicates master chefs' techniques and flavors. The company delivers a complete solution integrating robots, recipe programs, and smart kitchen management systems, enabling restaurants to scale operations while serving fresh, wok-fired dishes.The Meishan Lion has been deployed across restaurants, hotels, and other venues, partnering with leading catering brands. It has become the market leader in non-catering smart wok robots, achieving the highest shipment volume in its category.

XYZ Robotics was established in 2018 and is headquartered in Shanghai, China, with an R&D office in Boston, USA. The company's vision is "Pick Anything. Place Anywhere." Explore the boundaries of robotics and provide stable and efficient products. This is the dedicated pursuit of every XYZ-er.

The XYZ Robotics technical team is the only consecutive "Top 3" winner in the Amazon Robotics Challenge, for three consecutive years. With the world's leading deep learning, 3D vision, robot motion planning and other cutting-edge technologies, it provides logistics and manufacturing industries with more efficient, accurate, and easier-to-deploy flexible solutions. This includes small parts sorting, middle part de-stacking, and industrial loading and unloading.

Dimension5, founded in 2015, specializes in 3D real-time rendering technology. Its flagship product, D5 Render, based on Unreal Engine and NVIDIA RTX technology, achieves second-level rendering and is widely used in architecture, interior design, and landscaping. It became an NVIDIA global ISV partner in 2019 and released the AI space design tool D5 Hi in 2023.

Specializing in natural-looking everyday wear, moody is an avant-garde colored contact lenses brand that is inspired by the exploration and expression of our multi-facet inner self.

METiS Pharmaceuticals is a discovery technology and therapeutics company that has the potential to drive best-in-class drug assets in a wide range of therapeutic areas.
By integrating machine learning, quantum simulation, and high-throughput experimentation, we enable scientists to rapidly, comprehensively, and intelligently develop novel drug candidates.

Bota Bio, founded in 2019, is a synthetic biology innovator using AI-driven bioengineering for novel protein design and bio-manufacturing in medicine, food, and agriculture. Headquartered in Hangzhou, it also operates in the US.

SiBionics is a MedTech startup specialized in the R&D and commercialization of active implantable medical devices and medical artificial intelligence. Our company is headquartered in Shenzhen with additional R&D center and offices located in Los Angeles, Beijing and Guangzhou.

Our project pipeline includes Retinal Prosthesis, Continuous Glucose Monitoring, Diabetic Retinopathy Screening and Gastric Cancer Screening, covering major aspects of healthcare, from health and chronic conditions management, to disease screening, diagnostics and treatment.

Today, it is increasingly recognized that more and more unmet medical needs may be met by tackling the undruggable targets in the realm of drug discovery. Along with other novel approaches, allostery has shown its potential to open another window for drug developers to broaden and diversify the drug space. Allostery is an inherent property of biomacromolecules in which topographically distinct binding sites within a protein are functionally coupled. Allosteric modulation of proteins enables exquisite control over a number of biological processes, presenting itself as a unique solution for drug developers to aim at undruggable targets. Furthermore, recent allosteric drugs, both approved and those still in clinical development stages, have simply demonstrated allostery as a proven drug discovery approach. NUTSEHLL is a suite of AI-based tools built upon a deep understanding of allosteric mechanism since 2013, when the enriched allosteric database was established around 2009. Currently, this well-established technology platform, in particular, the work flow know-how（SMA，PMA and PPA）enable to implement a complete compound discovery process from identification of the potential allosteric site, and all the way through to hit and lead molecule discovery, in conjunction with a strong medicinal chemistry capability. Thus far, NUTSHELL has been generating its own pipeline as well as enabling other academic and industry collaborators to develop allosteric drug. With our NUTSHELL proprietary platform and its early stage yet fast evolving allosteric based pipelines, NUTSHELL biotech is now becoming an oncology focused and novel target centered company and pioneering in allosteric drug discovery.